Our Science
Innovative Research for a Breakthrough Sickle Cell Therapy
Imalia’s main product, IMA001, is a small molecule with an innovative dual mechanism of action. It directly targets the causes of red blood cell sickling, oxidative stress, and cell damage.
Our preclinical studies support IMA001 as a disease-modifying treatment, as it reduces vaso-occlusive crises (VOC) and prolongs red blood cell life, without major side effects.
Designed for both pediatric and adult patients, IMA001 aims to ease the burden of sickle cell disease for patients who currently have few therapeutic options.
Pioneering Research for Life-Changing SCD Therapy
Imalia’s lead product, IMA001, is an innovative small molecule featuring a novel dual mechanism of action (MoA) targeting the cellular mechanisms responsible for RBC sickling, oxidative stress, and hemolysis.
Our pre-clinical results show a significant reduction in vaso-occlusive crises (VOCs), prolonging RBC lifespan. IMA001 is positioned as a true disease-modifying therapy, all with no significant side effects reported.
Thanks to a formulation suitable to younger and adult Sickle Cell Disease populations, IMA001 aims to ease the burden of underserved populations.
Pioneering Research for Life-Changing SCD Therapy
Imalia’s lead product, IMA001, is an innovative small molecule featuring a novel dual mechanism of action (MoA) targeting the cellular mechanisms responsible for RBC sickling, oxidative stress, and hemolysis.
Our pre-clinical results show a significant reduction in vaso-occlusive crises (VOCs), prolonging RBC lifespan. IMA001 is positioned as a true disease-modifying therapy, all with no significant side effects reported.
Thanks to a formulation suitable to younger and adult Sickle Cell Disease populations, IMA001 aims to ease the burden of underserved populations.